the "capital position" without a significant takeup from retail may be the similar again within 6 months. or maybe slightly longer. depending on how much it costs to fund the back pain trial.
but the companies "strategic position" would alter significantly with favourable outcome/s from the multiple conversations with the fda in the next quarter.
feedback on assays for bla
pathways for heart failure and heart disease
and ghvd adults protocol
Ann: Information For Retail Shareholders, page-148
-
- There are more pages in this discussion • 394 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
-0.005(0.43%) |
Mkt cap ! $1.304B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.13 | $1.785M | 1.561M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 93520 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 44623 | 20 |
View Market Depth
| Last trade - 13.58pm 22/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |